Latest news
EU Approves Sanofi's MenQuadfi for Infants as Young as 6 Weeks, Expanding Protection Against a Leading Cause of Acquired Deafness - The Hearing ReviewThe Hearing Review · Fri, 07 Aug 2026 00:18:45 GMTSanofi (NASDAQ: SNY) gets EU approval to use MenQuadfi in infants - Stock TitanStock Titan · Thu, 06 Aug 2026 10:06:45 GMTSanofi’s MenQuadfi approval expanded to infants from six weeks in Europe - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Tue, 04 Aug 2026 13:39:01 GMTSanofi’s MenQuadfi approved in the EU for younger infants - The Pharma LetterThe Pharma Letter · Tue, 04 Aug 2026 10:26:53 GMTSanofi: MenQuadfi vaccine approved in the EU from six weeks of age - Idéal InvestisseurIdéal Investisseur · Tue, 04 Aug 2026 08:59:00 GMTPress Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 05:00:00 GMTSanofi’s MenQuadfi approved in EU for infants from six weeks - scanx.tradescanx.trade · Mon, 03 Aug 2026 07:00:00 GMTTolebrutinib Approved in EU for Nonrelapsing Secondary Progressive MS, Marking First Disability-Targeting Therapy in the Indication - neurologylive.comneurologylive.com · Mon, 03 Aug 2026 02:40:36 GMT